5601. Lumiracoxib

Nomenclature

CAS number: 220991-20-8
2-[(2-Chloro-6-fluorophenyl)amino]-5-methylbenzeneacetic acid; 5-methyl-2-(2′-chloro-6′-fluoroanilino)phenylacetic acid; COX-189; Prexige (Novartis).
C15H13ClFNO2; mol wt 293.72.
C 61.34%, H 4.46%, Cl 12.07%, F 6.47%, N 4.77%, O 10.89%.

Description and references

Selective cyclooxygenase-2 (COX-2) inhibitor. Prepn: R. A. Fujimoto et al., WO 9911605; eidem, US 6310099 (1999, 2001 both to Novartis). Clinical evaluation of gastroduodenal tolerability: C. Rordorf et al., Aliment. Pharmacol. Ther. 18, 533 (2003). Clinical experience in dysmenorrhea: M. Bitner et al., Int. J. Clin. Pract. 58, 340 (2004); in rheumatoid arthritis: P. Geusens et al. ibid. 1033; in tension headache: E. Packman et al., Headache 45, 1163 (2005). Review of clinical pharmacology: C. M. Rordorf et al., Clin. Pharmacokinet. 44, 1247-1266 (2005); of clinical experience in osteoarthritis: F. Berenbaum et al., J. Int. Med. Res. 33, 21-41 (2005); in osteoarthritis, rheumatoid arthritis, and dental pain: T. J. Schnitzer et al., Curr. Med. Res. Opin. 21, 151-161 (2005).

Chemical structure

Properties

mp 158-159°.

Therapeutic Category

Anti-inflammatory.

Keywords

Anti-inflammatory (Nonsteroidal); Cyclooxygenase-2 Selective Inhibitor